NCT05041153 2026-01-12
Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Recruiting
Clinical Trials
5 trialsNCT03153410 2025-01-09
Pilot Study With CY, Pembrolizumab, GVAX, and IMC-CS4 (LY3022855) in Patients With Borderline Resectable Adenocarcinoma of the Pancreas
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase EARLY_PHASE1 Completed
NCT03395847 2023-11-18
Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Completed
NCT04777708 2023-03-24
BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer
Jonsson Comprehensive Cancer Center
Phase EARLY_PHASE1 Terminated
NCT03099564 2023-02-06
Pembrolizumab Plus Y90 Radioembolization in HCC Subjects
Hoosier Cancer Research Network
Phase EARLY_PHASE1 Unknown